CN101549050B - Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN101549050B CN101549050B CN2008101031711A CN200810103171A CN101549050B CN 101549050 B CN101549050 B CN 101549050B CN 2008101031711 A CN2008101031711 A CN 2008101031711A CN 200810103171 A CN200810103171 A CN 200810103171A CN 101549050 B CN101549050 B CN 101549050B
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine composition
- processed
- rhizoma rhei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from radix astragali, ginseng fibrous root, prepared rhubarb, cattail pollen and radix puerariae according to a certain weight ratio and can be prepared into any commonly used orally taking dosage forms. The traditional Chinese medicine composition has the efficacies of tonifying qi, promoting the blood circulation, removing the blood stasis, relaxing veins, moistening diarrhea and dredging the viscera and is used for treating the cardiovascular and cerebrovascular diseases such as cerebral arteriosclerosis, hypertension, coronary heart diseases, and the like.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used to treat cardiovascular and cerebrovascular disease and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Ischemic cerebrocardiac disease is the commonly encountered diseases of harm people ' s health, in case death rate of the onset is high, disability rate is high.In recent years, because the progress of Hemorheology Study and extensively apply to has clinically had understanding further to the formation reason and the treatment of primary disease.
The geographic epidemiological study of U.S. Framingham has been carried out the investigation of coronary heart disease and apoplexy incidence rate and has been followed up a case by regular visits to work the normal and unusual crowd of HC; The result finds that coronary heart disease and occurrence of stroke are along with increasing of HC level, and has at first proposed increasing of HC and red blood cell hematocrit and can indicate that coronary heart disease and apoplexy take place.Blood viscosity is mainly first with erythrocyte number, size, deformability and plasma fibrin, the blood fat equal size is relevant; Owing to packed cell volume increases, the low inferior reason of ED causes blood viscosity to increase; Resistance of blood flow strengthens, and erythrocyte aggregation and platelet aggregation are strengthened, and causes microcirculation disturbance; Form thrombosis, cause primary disease to take place.
Therefore can think that high blood viscosity is the pathogenesis basis of ischemic angiocardiopathy and cerebrovascular, adopt blood viscosity lowering, improve the method for platelet aggregation, can prevent the generation of ischemic cerebrocardiac disease.
The traditional Chinese medical science is thought " the gas promoting the circulation of blood is then gone; deficiency of vital energy blood then coagulates for qi being the governor of blood, blood being the material foundation of QI "; The deficiency of vital energy does not have the circulation of force urges blood in arteries and veins so blood stasis is, has made it to lose the physiological feature of " pulse felt like the flowing of water without return ", and becomes the capable mistake degree of the blood state of " blood stasis and do not flow ".And the said blood of the traditional Chinese medical science becomes " not flowing " by " stream ", and from hemorheological viewpoint of measures, blood is as flowability and the not normal result of viscosity that a kind of fluid had just.
So; Develop a kind of benefiting QI for activating blood circulation, blood stasis dispelling purging FU-organs; Reduce WBV, plasma viscosity, packed cell volume, fibronectin and lipids contents; Improve ED, change the Chinese medicine composition of erythrocyte and hematoblastic aggregation, thereby the ischemic cerebrocardiac disease that control causes because of the hemorheology sexual abnormality is very important.
Summary of the invention
The purpose of this invention is to provide a kind of new Chinese medicine composition, said composition has the function that benefiting QI for activating blood circulation, blood stasis dispelling and network, profit are rushed down purging FU-organs, is used to treat cardiovascular and cerebrovascular diseases such as cerebral arteriosclerosis, hypertension, coronary heart disease.
Another object of the present invention provides the method for preparing of above-mentioned Chinese medicine composition.
The 3rd purpose of the present invention provides the application of said medicine in cardiovascular and cerebrovascular diseases medicaments such as preparation treatment cerebral arteriosclerosis, hypertension, coronary heart disease.
The present invention realizes through following technical scheme:
The present invention is processed by the raw material of following weight parts: Radix Astragali 1-30 part, Leptoradix Ginseng 0.5-10 part, Radix et Rhizoma Rhei (processed) 0.5-10 part, Pollen Typhae 0.5-10 part, Radix Puerariae 1-20 part.
Preferred weight portion is: Radix Astragali 5-20 part, Leptoradix Ginseng 1-5 part, Radix et Rhizoma Rhei (processed) 1-5 part, Pollen Typhae 1-5 part, Radix Puerariae 2-10 part.
Wherein: the Leptoradix Ginseng is preferably fibrous root of Radix Ginseng, and the Leptoradix Ginseng can also replace with Radix Ginseng; Radix et Rhizoma Rhei (processed) can also replace with Radix Et Rhizoma Rhei.
The method for preparing of Chinese medicine composition of the present invention is following:
Said bulk drugs is added water or Different concentrations of alcohol extraction respectively; The extracting solution concentrate drying gets crude extract; Or directly pulverizing obtains medicinal powder; Or the employing process for purification, for example, decoction and alcohol sedimentation technique, organic solvent extractionprocess, column chromatography, carbon dioxide supercritical extraction method, steam distillation are made with extra care and are obtained extract; Required various conventional adjuvant when above-mentioned crude extract or medicinal powder or extract are added the preparation different dosage form; Like diluent, disintegrating agent, excipient, binding agent, lubricant, surfactant, filler, antiseptic, stabilizing agent, correctives, thickening agent, fluidizer etc.; Method of Chinese medicinal with routine is prepared into any common formulations, like tablet, dispersible tablet, effervescent tablet, oral cavity disintegration tablet, buccal tablet, chewable tablet, capsule, soft capsule, microcapsule, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid, injection etc.
Chinese medicine composition preferred manufacturing procedure of the present invention is following:
With Radix Astragali water extraction, concentrating under reduced pressure; Leptoradix Ginseng, Pollen Typhae, Radix Puerariae extract with Different concentrations of alcohol respectively, decompression recycling ethanol; Radix Et Rhizoma Rhei powder is broken into fine powder or micropowder; Mix; Drying is ground into fine powder, adds adjuvant, processes tablet.
The special preferred manufacturing procedure of Chinese medicine composition of the present invention is following:
8 times of water gagings of the Radix Astragali are extracted 3 times, each 1 hour, concentrating under reduced pressure; Leptoradix Ginseng, Pollen Typhae, Radix Puerariae are measured 70% ethanol extraction 3 times for 8 times, and each 1 hour, decompression recycling ethanol; Radix Et Rhizoma Rhei powder is broken into fine powder or micropowder; Mix; Drying is ground into fine powder, adds adjuvant, processes tablet, the bag film-coat.
Drug mechanism of the present invention is following:
The Radix Astragali: sweet, warm.Return lung, spleen channel.Effect with invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Main component is flavones ingredient, Saponin class, polysaccharide, aminoacid, betanin, beta-sitosterol, vitamins etc.Pharmacological evaluation shows that the Radix Astragali has the blood of reduction specific viscosity, packed cell volume, can obviously improve ED, suppresses the activity of platelet calmodulin, CaM medicine.Improve myocardial function, regulate body's immunity, antiinflammatory, defying age and anti-stress.
The Leptoradix Ginseng: sweet, little hardship, flat.Return spleen, lung, heart channel.Have that strongly invigorating primordial QI, multiple arteries and veins take off admittedly, invigorating the spleen to benefit the lung, the effect of promoting the production of body fluid, calming the nerves.Main component is ginsenoside etc.Pharmacological evaluation shows; Radix Ginseng has the myocardial function of improvement; The Fibrinogen of thrombin induction is converted into fibrin has inhibitory action, can reduce WBV, plasma viscosity, Trombin inhibiting and arachidonic acid-induction platelet aggregation, suppress collagen-induced platelet aggregation, suppress the inductive platelet aggregation of ADP.Regulate hypophysis-interrenal system function, regulate immunologic function etc.
Radix et Rhizoma Rhei (processed) (claiming Radix Et Rhizoma Rhei again): hardship, cold.Return spleen, stomach, large intestine, liver, pericardium channel.Effect with purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.Main component is anthraquinone derivatives, tannin and other composition.Pharmacological evaluation shows that Radix Et Rhizoma Rhei can reduce blood viscosity, red blood cell hematocrit and WBV, has anticoagulant, blood fat reducing, the anti-ageing effect of waiting for a long time.
Pollen Typhae: sweet, flat.Return liver, pericardium channel.Have hemostasis, blood stasis dispelling, treating stranguria effect.Main component is flavonoid, steroid class, fatty acid, aminoacid etc.Pharmacological evaluation shows, Pollen Typhae has blood fat reducing, reduce platelet aggregation, fibrinolytic, protection vascular endothelial cell, improve effect such as cardiac muscle.
Radix Puerariae: sweet, hot, cold.Return spleen, stomach warp.Have expelling pathogenic factors from muscles for reducing heat, promote the production of body fluid, the effect of rash, yang invigorating antidiarrheal.Main component is a flavones ingredient etc.Pharmacological evaluation shows, effect such as Radix Puerariae has the coronary circulation of improvement, improves myocardial function, anticoagulant.
Chinese medicine composition of the present invention is reused the Radix Astragali with QI invigorating, and the prosperous blood of gas is also gone, and blood stasis dispelling and just not hindering is monarch drug; Fibrous root of Radix Ginseng helps Radix Astragali QI invigorating, the Radix et Rhizoma Rhei (processed) blood circulation promoting and blood stasis dispelling, and the double purging FU-organs that can purge heat is ministerial drug altogether; The Pollen Typhae blood stasis dispelling, the ability of holding concurrently promoting the circulation of QI to relieve pain, Radix Puerariae lightly floats to rise and sends out, and inspires gastric qi, and middle gas is promptly sufficient, and clear sun rises.All medicines share, benefiting QI for activating blood circulation, and the prosperous blood of gas is capable, the stasis of blood ruton of dispelling.
Chinese medicine composition of the present invention has the effect that benefiting QI for activating blood circulation, blood stasis dispelling and network, profit are rushed down purging FU-organs.Be used to treat syndrome of blood stasis due to qi deficiency, disease is seen dizzy dizziness, distending pain in the head, severe palpitation, feeling of oppression and pain in the chest, scalp or numb limbs and tense tendons, hypomnesis, constipation, purplish tongue, or ecchymosis is arranged, hesitant pulse, or tie generation.Be used to treat cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, cerebral arteriosclerosis, apoplexy and sequela thereof, hypertension, hyperlipidemia, high blood viscosity, coronary heart disease, angina pectoris, arrhythmia, atherosclerosis, the senile dementia person that sees the above-mentioned symptom.Also can be used for other disease person that sees the above-mentioned symptom.
Below, foregoing of the present invention is done further to specify through the specific embodiment:
The specific embodiment
Embodiment 1:
Radix Astragali 1g, Radix Ginseng 0.5g, Radix Et Rhizoma Rhei 0.5g, Pollen Typhae 0.5g, Radix Puerariae 1g
The pulverizing medicinal materials of above-mentioned weight proportion is become fine powder, add proper honey, process honeyed pill.
Embodiment 2:
Radix Astragali 30g, Leptoradix Ginseng 10g, Radix et Rhizoma Rhei (processed) 10g, Pollen Typhae 10g, Radix Puerariae 20g
The medical material of above-mentioned weight proportion is suitably pulverized, added the ethanol of 8 times of amounts 70%, extract each 1 hour 3 times; Filter, merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure;-0.08Mpa), be ground into fine powder, add an amount of dextrin, evenly mixed; Adding 95% alcoholic solution is wetting agent, granulates, and drying promptly gets granule.
Embodiment 3:
Radix Astragali 5g, Leptoradix Ginseng 1g, Radix et Rhizoma Rhei (processed) 1g, Pollen Typhae 1g, Radix Puerariae 2g
The Radix Astragali, Radix Puerariae are added 8 times of water gagings, extract 3 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa); Be ground into fine powder, add the fine powder of Leptoradix Ginseng, Radix et Rhizoma Rhei (processed), Pollen Typhae, add lactose, mixing; Use 95% alcohol granulation, drying incapsulates, and promptly gets capsule.
Embodiment 4:
Radix Astragali 20g, Leptoradix Ginseng 5g, Radix et Rhizoma Rhei (processed) 5g, Pollen Typhae 5g, Radix Puerariae 10g
The medical material of above-mentioned weight proportion is added 8 times of water gagings, extract 3 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa); Be ground into fine powder, add tartaric acid, sodium bicarbonate, stevioside, xylitol mixing, granulate drying with dehydrated alcohol; Add magnesium stearate, mixing, compacting promptly gets effervescent tablet in flakes.
Embodiment 5:
Radix Astragali 10g, Leptoradix Ginseng 3g, Radix et Rhizoma Rhei (processed) 3g, Pollen Typhae 2g, Radix Puerariae 6g
The medical material of above-mentioned weight proportion is added 8 times of water gagings, extract 3 times, each 1 hour, filter merging filtrate; Add 95% ethanol and make and contain alcohol amount and reach 50%, the cold preservation hold over night is got supernatant, and being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure;-0.08Mpa), be ground into fine powder, add lactose, mixing; Use 95% alcohol granulation, drying incapsulates, and promptly gets capsule.
Embodiment 6:
Radix Astragali 12g, Leptoradix Ginseng 4g, Radix et Rhizoma Rhei (processed) 3g, Pollen Typhae 3g, Radix Puerariae 7g
The medical material adding of above-mentioned weight proportion is measured 80% ethanol for 10 times, extract 2 times, each 1 hour, filter merging filtrate; Being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), be ground into fine powder; Add low-substituted hydroxypropyl cellulose, microcrystalline Cellulose, calcium bicarbonate, the mode mixing that increases progressively with equivalent; Use 50% alcohol granulation, drying, compacting promptly gets dispersible tablet in flakes.
Embodiment 7:
Radix Astragali 15g, Leptoradix Ginseng 5g, Radix et Rhizoma Rhei (processed) 4g, Pollen Typhae 4g, Radix Puerariae 8g
The Radix Astragali, Radix Puerariae, Pollen Typhae, Radix et Rhizoma Rhei (processed) are added 8 times of water gagings, extract 3 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure;-0.08Mpa), be ground into fine powder, add Leptoradix Ginseng's fine powder; Add proper honey, evenly mixed, the pill agent.
Embodiment 8:
Radix Astragali 10g, Leptoradix Ginseng 3g, Radix et Rhizoma Rhei (processed) 2g, Pollen Typhae 2g, Radix Puerariae 5g
The Radix Astragali is added 8 times of water gagings extract 3 times, each 1 hour, filter merging filtrate; Leptoradix Ginseng, Radix Puerariae, Pollen Typhae are added 8 times of amount 70% ethanol respectively, extract 3 times, each 1 hour, filter merging filtrate; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), adds the micropowder of Radix et Rhizoma Rhei (processed), drying under reduced pressure (60 ℃ ,-0.08Mpa); Be ground into fine powder, add lactose, starch is an amount of, mixing is granulated drying; Add magnesium stearate, mixing, tabletting, the bag film-coat promptly gets tablet.
Embodiment 9:
Radix Astragali 8g, Leptoradix Ginseng 2g, Radix et Rhizoma Rhei (processed) 1g, Pollen Typhae 1g, Radix Puerariae 4g
The Radix Astragali, Radix Puerariae, Pollen Typhae, Leptoradix Ginseng are added 8 times of amount 70% ethanol, extract 3 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa); Be ground into fine powder, add the micropowder of Radix et Rhizoma Rhei (processed), add an amount of dextrin, evenly mixed; Adding 95% alcoholic solution is wetting agent, granulates, and drying promptly gets granule.
Embodiment 10:
Radix Astragali 6g, Leptoradix Ginseng 2g, Radix et Rhizoma Rhei (processed) 1g, Pollen Typhae 2g, Radix Puerariae 5g
The Radix Astragali, Radix Puerariae, Pollen Typhae, Radix et Rhizoma Rhei (processed) are added 10 times of amount 70% ethanol, extract 2 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure;-0.08Mpa), be ground into fine powder, add Leptoradix Ginseng's fine powder; Add proper honey, evenly mixed, the pill agent.
Embodiment 11:
Radix Astragali 14g, Leptoradix Ginseng 3g, Radix et Rhizoma Rhei (processed) 2g, Pollen Typhae 2g, Radix Puerariae 6g
The medical material of above-mentioned weight proportion is added 8 times of water gagings, extract 3 times, each 1 hour, filter; Merging filtrate adds 95% ethanol and makes and contain alcohol amount and reach 50%, and the cold preservation hold over night is got supernatant; Suitably concentrate, add an amount of saccharin sodium, essence, sodium benzoate, sorbitol, tween 80, mix; Add the water standardize solution, packing promptly gets oral liquid.
Embodiment 12:
Radix Astragali 25g, Leptoradix Ginseng 5g, Radix et Rhizoma Rhei (processed) 3g, Pollen Typhae 5g, Radix Puerariae 10g
The Radix Astragali is added 10 times of water gagings extract 2 times, each 1 hour, filter merging filtrate; Leptoradix Ginseng, Radix Puerariae, Pollen Typhae are added 8 times of amount 75% ethanol, extract 3 times, each 1 hour, filter; Merging filtrate, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure;-0.08Mpa), be ground into fine powder, add the micropowder of Radix et Rhizoma Rhei (processed); Add proper honey, evenly mixed, the pill agent.
Come further to set forth the beneficial effect of Chinese medicine composition according to the invention through following experiment:
One, clinical research:
1. case is selected
Selection meets the ischemic cerebrocardiac disease diagnostic criteria, and hematocrit, plasma viscosity, WBV height cut when that WBV is low cuts ratio, fibronectin in the hemorheology index, and any 3 paranormal blood viscositys increase the patient in 5 indexs.Giddy or dizzy can appear in clinical manifestation, feeling of fullness in the head or pain, and severe palpitation, uncomfortable in chest or pain, numbness of scalp, in the numb limbs and tense tendons any two, or doublely see corresponding tongue, arteries and veins.
2. divide into groups and medication
Observe 84 examples altogether.(1) 66 examples are organized in treatment: male 51 examples, women 15 examples; Minimum 26 years old of age, maximum 71 years old, average 55.2 ± 11.6 years old; Hypertension 11 examples, hyperlipidemia 6 examples, cerebral thrombosis 10 examples, cerebral infarction 11 examples, coronary heart disease 10 examples, cerebral arteriosclerosis 18 examples.The tablet that oral Chinese medicine composition of the present invention (embodiment 8) is processed, every 0.5g 3 times on the 1st, each 2, serve on 1 month.(2) matched group 18 examples: male 15 examples, women 3 examples; Minimum 60 years old of age, maximum 82 years old, average 69.4 ± 6.59 years old; Hypertension 6 examples, coronary heart disease 3 examples, cerebral arteriosclerosis 5 examples, cerebral infarction 4 examples.Oral cerebral circulation metabolism improving agent KALAN PIAN (Japan produces, Tianjin Sheng Li pharmaceutical factory packing) treatment.Every 5mg, each 1, every day 2 times, 1 month course of treatment.All before and after treatment, respectively survey hemorheology index 1 time for two groups; Stop using to influential other Chinese and western drugses of hemorheology index during the treatment.
3. hemorheology index is measured
Extract fasting blood early morning, under 25 ℃ of constant temperature, with the hemorheology series instrument of Shanghai Medical Students thing physics teaching and research room development: LIANG-100 type hemorheology analyzer; LIANG-100 type erythrocyte electrophoresis analyzer; DXC-300A type ED analyzer; XJ-F type platelet aggregation instrument; The TDL-5 cell separator is measured, and concrete data are measured by the sick laboratory research personnel of heart and brain and calculated and report.
4. statistical method
Adopt X2 and t check.
5. result
5.1 the change of hemorheology index before and after the traditional Chinese medicine composition for treating of the present invention
Treatment is organized 66 routine patients through taking Chinese medicine composition of the present invention after 1 month, and hemorheology index all has obvious change (seeing table 1).
5.2 the comparative analysis of two groups of treatment back hemorheology index error numbers
With traditional Chinese medicine composition for treating 66 examples of the present invention, with the blue treatment of card 18 examples, two groups of treatment back hemorheology indexs all change (seeing table 2).
5.3 main clinic symptoms is improved situation
Symptom to ischemic cerebrocardiac disease is carried out the fuzzy mathematics classification, be about to each information be divided into normally, light, in, the weight level Four, gradation factor is 0; 1; 2; 3.Existing curative effect score value with clinical symptoms treatment front and back compares (seeing table 3).Glucose recovery calculates its clinical symptoms improvement rate (seeing table 4) to the case load below slight (containing slight) before and after will treating simultaneously.
Hemorheology index analytical table before and after table 1 traditional Chinese medicine composition for treating of the present invention:
Hemorheology index comparative analysis before and after the table 2 liang group treatment:
The integrated value comparison sheet of main clinic symptoms before and after table 3 treatment:
Main clinic symptoms improvement rate analytical table before and after table 4 treatment:
Can know among the table 1-4 that after the ischemic cerebrocardiac disease treatment of Chinese medicine composition of the present invention to high blood viscosity, clinical symptoms improves significantly, the integrated value before and after its treatment relatively has the difference of highly significant.After the treatment of the unusual cardiovascular and cerebrovascular disease of hemorheology index, significant clinical efficacy is arranged, the improvement rate before and after its symptom treatment is all more than 84.7%.
Two, pharmacological research:
1. materials and methods
The SD rat, 250g-300g, senile rat 450g-500g, male and female dual-purpose; Livid purple blue rabbit: 2kg-2.5kg, male and female are regardless of, and Nanjing Railway College of Medicine's animal center provides.The same clinical research of instrument.Reagent: Chinese medicine composition tablet of the present invention, KALAN PIAN (same clinical research), adrenalin hydrochloride injection, lot number 960304, Wuhan Pharmacy stock Co., Ltd; ADP, lot number 961833, method is homemade.Method: research worker is made animal model under the condition of strictness, get animal hearts blood, carries out anticoagulant, accomplishes experiment at the appointed time.
2. result
2.1 influence to blood stasis due to qi deficiency rat model hemorheological property
Get 50 of healthy rats, male and female half and half are divided equally 5 groups, 10 every group, set up normal control group, model control group, Chinese medicine composition high dose group of the present invention, Chinese medicine composition low dose group of the present invention, KALAN PIAN group.Successive administration 10d, except that the normal control group, each organizes rat, and to put water temperature every day be swimming 1 time in 42 ℃ ± 1 ℃ the water tank; Naturally till sinking unable emersion to it, 10d continuously, each Mus is anaesthetized with pentobarbital sodium during 11d; Heart extracting blood is surveyed its hemorheological indexes, and the result sees table 5.
Table 5 Chinese medicine composition of the present invention causes the influence
of " blood stasis due to qi deficiency " hemorheology of rat to continuous swimming
| Group | Dosage g/kg | WBV (height is cut) | WBV (height is cut) | Plasma viscosity (ratio) | Serum viscosity in rabbits (ratio) | Packed cell volume (%) | Erythrocyte electrophoretic time (S) |
| Normal control | - | 8.99± 1.15 ** | 23.47±4.96 ** | 1.75±0.09 ** | 1.61±0.07 ** | 41.25±4.16 ** | 20.65±1.56 ** |
| The model contrast | - | 11.08 ±1.48 | 33.90±5.24 | 1.98±0.23 | 1.79±0.11 | 48.10±5.74 | 24.32±1.99 |
| Chinese medicine composition high dose of the present invention | ?4 | 7.36± ?1.33 ** | ?16.06±4.79 ** | ?1.71±0.07 ** | ?1.60±0.07 ** | ?41.00±6.27 ** | ?21.90±1.41 ** |
| Chinese medicine composition low dosage of the present invention | ?2 | 9.16± ?1.66 * | ?20.34±5.65 ** | ?1.77±0.12 ** | ?1.63±0.08 ** | ?43.11±6.82 | ?22.31±1.87 * |
| KALAN PIAN | 0.01 | 8.62± 1.24 ** | 19.27±4.35 ** | 1.74±0.18 ** | 1.61±0.12 ** | 41.58±5.73 ** | 22.45±1.66 * |
Annotate: * P＜0.05, * * P＜0.01 (comparing) with model control group.
The result shows; Force rat in warm water continuously behind the swimming 10d; Tangible blood stasis due to qi deficiency symptom appears in animal, and hemorheology detects and shows that its each item index all obviously raises than normal group, and administration group each item index and model group significantly reduce (P＜0.05; P＜0.01), Chinese medicine composition group of the present invention shows certain dose-effect relationship.Chinese medicine composition group of the present invention and KALAN PIAN group be no significant difference (P＜0.05) relatively.
2.2 influence to the senile rat ED
Get 40 of healthy geriatric rats, male and female are regardless of, and divide equally 4 groups, 10 every group, set up normal control group, Chinese medicine composition high dose group of the present invention, Chinese medicine composition low dose group of the present invention, KALAN PIAN group.Successive administration 10d, each Mus of 11d is anaesthetized with pentobarbital sodium, heart extracting blood 3ml; Obtain hematocrit and be 0.5% red blood cell suspension as supplying ED to measure the sample of usefulness, with IF (erythrocyte FI) reflection ED size.The IF value is big more, show that ED more a little less than; Otherwise the IF value is few more, shows that ED is strong more.IF=tB-tW/5 * tW (result sees table 6).
Table 6 Chinese medicine composition of the present invention is to the influence
of senile rat ED
Can know that by table 6 Chinese medicine composition of the present invention and KALAN PIAN all can make the senile rat ED obviously increase (P＜0.01), no significant difference between the administration group.Have certain dose-effect relationship between the Chinese medicine composition high and low dose group of the present invention, ED influences the operation and the circulation of blood and effectively pours into, the ED of Chinese medicine composition ability enhancing body of the present invention.
2.3 the normal rabbits platelet aggregation is influenced
Get 18 of livid purple blue rabbit, male and female are regardless of, and are divided into 3 groups, 6 every group, set up normal control group, Chinese medicine composition group of the present invention, KALAN PIAN group.Successive administration 10d, after the last administration next day heart extracting blood once more, measure each rabbit platelet PAR according to preceding method, each group is carried out front and back and is compared, the result sees table 7.
Table 7 Chinese medicine composition of the present invention is to the influence
of normal rabbits ADP induced platelet aggregation capability
The result shows that Chinese medicine composition of the present invention and KALAN PIAN all can obviously reduce the platelet aggregation property (P＜0.01) of rabbit, relatively reaches relatively no significant difference (P＞0.05) of Chinese medicine composition of the present invention and KALAN PIAN group before and after the matched group.
2.4 to the thrombotic influence that circulates of normal rats in vitro
Get 40 of healthy rats, male and female are regardless of, and are divided into 4 groups, 10 every group, set up normal control group, Chinese medicine composition high dose group of the present invention, Chinese medicine composition low dose group of the present invention, KALAN PIAN group.Successive administration 10d, during 11d, each is organized rat and anaesthetizes with pentobarbital sodium, and back of the body position is fixing, separates RCCA and left external jugular vein, measures wet weight of thrombus, and the result sees table 8.
The influence
that table 8 Chinese medicine composition of the present invention forms normal rats in vitro circulation blood examination
The result shows that Chinese medicine composition of the present invention and KALAN PIAN all can obviously suppress formation (P＜0.01, P＜0.05), Chinese medicine composition of the present invention and the KALAN PIAN group no significant difference (P＞0.05) of thrombosis in the animal extracorporeally circulating blood.Chinese medicine composition high dose group of the present invention effect obviously is better than low dose group, explains that these article have the obvious suppression effect to thrombosis.
Clinical and pharmacological evaluation conclusion: the clinical observation of Chinese medicine composition of the present invention shows; The ischemic cerebrocardiac disease hemorheology index is really improved significantly; Especially can reduce WBV, plasma viscosity, packed cell volume, fibronectin and lipids contents; ED be can improve, erythrocyte and hematoblastic aggregation changed.Find that simultaneously along with the improvement of hemorheology index, patient's symptom also obviously alleviates.Zoopery is the result show, Chinese medicine composition of the present invention has obvious change hemorheological indexes, and blood viscosity lowering and platelet aggregation property improve ED and antithrombotic effect.The ischemic cerebrocardiac disease that causes because of the hemorheology sexual abnormality with Chinese medicine composition control of the present invention has obtained very satisfied curative effect.
Claims (8)
1. a Chinese medicine composition of treating cardiovascular and cerebrovascular disease is characterized in that, it is to be processed by following bulk drugs: Radix Astragali 1-30 part, Leptoradix Ginseng 0.5-10 part, Radix et Rhizoma Rhei (processed) 0.5-10 part, Pollen Typhae 0.5-10 part, Radix Puerariae 1-20 part.
2. according to the Chinese medicine composition of claim 1, it is characterized in that it is to be processed by following bulk drugs: Radix Astragali 5-20 part, Leptoradix Ginseng 1-5 part, Radix et Rhizoma Rhei (processed) 1-5 part, Pollen Typhae 1-5 part, Radix Puerariae 2-10 part.
3. according to the Chinese medicine composition of claim 1, it is characterized in that it is to be processed by following bulk drugs: 10 parts of the Radixs Astragali, 3 parts of Leptoradix Ginsengs, 2 parts of Radix et Rhizoma Rhei (processed), 2 parts of Pollen Typhaes, 5 parts of Radix Puerariaes.
4. a Chinese medicine composition of treating cardiovascular and cerebrovascular disease is characterized in that, it is to be processed by following bulk drugs: Radix Astragali 1-30 part, Radix Ginseng 0.5-10 part, Radix et Rhizoma Rhei (processed) 0.5-10 part, Pollen Typhae 0.5-10 part, Radix Puerariae 1-20 part.
5. a Chinese medicine composition of treating cardiovascular and cerebrovascular disease is characterized in that, it is to be processed by following bulk drugs: Radix Astragali 1-30 part, Leptoradix Ginseng 0.5-10 part, Radix Et Rhizoma Rhei 0.5-10 part, Pollen Typhae 0.5-10 part, Radix Puerariae 1-20 part.
6. the method for preparing of any described Chinese medicine composition among the claim 1-3 is characterized in that this method is: said materials of weight proportions medicine is directly pulverized obtained medicinal powder; Or adding water or Different concentrations of alcohol extraction respectively, the extracting solution concentrate drying gets crude extract; Or adopt decoction and alcohol sedimentation technique, organic solvent extractionprocess, column chromatography, carbon dioxide supercritical extraction method, steam distillation to make with extra care and obtain extract; Above-mentioned medicinal powder or crude extract or extract are mixed with adjuvant, process any medicament on the pharmaceutics.
7. the method for preparing of Chinese medicine composition according to claim 6 is characterized in that, this method is: with Radix Astragali water extraction, concentrating under reduced pressure; Leptoradix Ginseng, Pollen Typhae, Radix Puerariae extract with Different concentrations of alcohol respectively, decompression recycling ethanol; Radix et Rhizoma Rhei (processed) is ground into fine powder or micropowder; Mix; Drying is ground into fine powder, adds adjuvant, processes any medicament on the pharmaceutics.
8. the method for preparing of Chinese medicine composition according to claim 7 is characterized in that, this method is: 8 times of water gagings of the Radix Astragali are extracted 3 times, and each 1 hour, concentrating under reduced pressure; Leptoradix Ginseng, Pollen Typhae, Radix Puerariae are measured 70% ethanol extractions 3 times with 8 times respectively, and each 1 hour, decompression recycling ethanol; Radix et Rhizoma Rhei (processed) is ground into fine powder or micropowder; Mix; Drying is ground into fine powder, adds adjuvant, processes tablet, the bag film-coat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101031711A CN101549050B (en) | 2008-04-01 | 2008-04-01 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101031711A CN101549050B (en) | 2008-04-01 | 2008-04-01 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101549050A CN101549050A (en) | 2009-10-07 |
| CN101549050B true CN101549050B (en) | 2012-03-21 |
Family
ID=41153693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101031711A Active CN101549050B (en) | 2008-04-01 | 2008-04-01 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101549050B (en) |
-
2008
- 2008-04-01 CN CN2008101031711A patent/CN101549050B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101549050A (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357136A (en) | Composition of traditional Chinese medicine effective constituent for preventing and treating diseased associated with cerebral ischemia injury | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN102488838B (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN104225403A (en) | Pharmaceutical composition for treating phthisis as well as preparation method and application thereof | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN100509010C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
| CN115414458A (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN101549050B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102988779A (en) | Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition | |
| CN103191243B (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101129431A (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same | |
| CN100464773C (en) | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180228 Address after: 102206 Beijing City, Changping District small town life Zhongguancun Life Science Park Road No. 8 School District No. 15 Building 5 layer Patentee after: Beijing YingKeRui Pharmaceutical Safety and Effectiveness Research Co.,Ltd. Address before: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee before: Beijing Increasepharm Co.,Ltd. |
|
| TR01 | Transfer of patent right |